Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Residual Renal Function in Peritoneal Dialysis
NCT06398977Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in end stage renal disease (ESRD) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Change in 24 urine volume at 24 weeks. Started Mar 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT06398977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398977.